Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: Summary of pharmacokinetics and biological and virological effects

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 9, 2008, Pages 3144-3160

  Van Rompay, Koen K A ^a   Durand Gasselin, Lucie ^b   Brignolo, Laurie L ^a   Ray, Adrian S ^b   Abel, Kristina ^a   Cihlar, Tomas ^b   Spinner, Abigail ^a   Jerome, Christopher ^c   Moore, Joseph ^a   Kearney, Brian P ^b   Marthas, Marta L ^a   Reiser, Hans ^b   Bischofberger, Norbert ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GILEAD SCIENCES   (United States)

^c Allevia AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ARGININE; LYSINE; TENOFOVIR; TENOFOVIR DISOPROXIL;

ADULT ANIMAL; ADULTHOOD; ALOPECIA; AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BONE DENSITY; CHEMICAL ANALYSIS; CODON; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSURIA; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOPHOSPHATEMIA; INFANCY; KIDNEY DYSFUNCTION; KIDNEY PROXIMAL TUBULE; KIDNEY PROXIMAL TUBULE DYSFUNCTION; MALE; NEPHROTOXICITY; NEWBORN; NEWBORN SEPSIS; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; PROGENY; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; URINALYSIS; VIREMIA;

ADENINE; AGE FACTORS; ANIMALS; ANTI-HIV AGENTS; DISEASE MODELS, ANIMAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MACACA MULATTA; PHOSPHONIC ACIDS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; REVERSE TRANSCRIPTASE INHIBITORS; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 50949121086     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00350-08     Document Type: Article

References (72)

1. AIDS Vaccine Advocacy Coalition. March 2005, posting date. Will a pill a day prevent HIV? Anticipating the results of the tenofovir "PREP" trials. http://avac.org/pdf/tenofovir.pdf.
2. Alatrakchi, N., C. Duvivier, D. Costagliola, A. Samri, A. Marcelin, G. Kamkamidze, M. Astriti, R. Agher, V. Calvez, B. Autran, and C. Katlama. 2005. Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication. AIDS 19:25-33.
3. Antiretroviral Pregnancy Registry Steering Committee. 2007. Antiretroviral Pregnancy Registry interim report for 1 January 1989 through 31 July 2007. Registry Coordinating Center, Wilmington, NC.
4. Barditch-Crovo, P., S. G. Deeks, A. Collier, S. Safrin, D. F. Coakley, M. Miller, B. P. Kearney, R. L. Coleman, P. D. Lamy, J. O. Kahn, I. McGowan, and P. S. Lietman. 2001. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob. Agents Chemother. 45:2733-2739.
5. Bedard, J., S. May, M. Lis, L. Tryphonas, J. Drach, J. Huffman, R. Sidwell, L. Chan, T. Bowlin, and R. Rando. 1999. Comparative study of the anti-human cytomegalovirus activities and toxicities of a tetrahydrofuran phosphonate analogue of guanosine and cidofovir. Antimicrob. Agents Chemother. 43:557-567.
6. Benech, H., F. Theodore, A. Herbet, N. Page, D. Schlemmer, A. Pruvost, J. Grassi, and J. R. Deverre. 2004. Peripheral blood mononuclear cell counting using a DNA-detection-based method. Anal. Biochem. 330:172-174.
7. Betts, M. R., and R. A. Koup. 2004. Detection of T-cell degranulation: CD107a and b. Methods Cell Biol. 75:497-512.
8. Blaas, S., A. Schneidewind, T. Gluck, and B. Salzberger. 2006. Acute renal failure in HIV patients with liver cirrhosis receiving tenofovir: a report of two cases. AIDS 20:1786-1787.
9. Brogly, S. B., N. Ylitalo, L. M. Mofenson, J. Oleske, R. Van Dyke, M. J. Crain, M. J. Abzug, M. Brady, P. Jean-Philippe, M. D. Hughes, and G. R. Seage III. 2007. In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children. AIDS 21:929-938.
10. Buxbaum, S., F. B. Kraus, A. Hahn, O. Beck, B. Kabartas, H. W. Doerr, and B. Ludwig. 2006. Flow cytometric analysis of virus-specific T lymphocytes: practicability of detection of HCMV-specific T lymphocytes in whole blood in patients after stem cell transplantation. J. Immunol. Methods 311:164- 173.
11. Calcagno, P. L., and M. I. Rubin. 1963. Renal extraction of para-aminohippurate in infants and children. J. Clin. Investig. 42:1632-1639.
12. Cassetti, I., J. V. Madruga, J. M. Suleiman, A. Etzel, L. Zhong, A. K. Cheng, and J. Enejosa. 2007. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV-1-infected patients. HIV Clin. Trials 8:164-172.
13. Chappell, B. J., N. A. Margot, and M. D. Miller. 2007. Long-term follow-up of patients taking tenofovir DF with low-level HIV-1 viremia and the K65R substitution in HIV-1 RT. AIDS 21:761-763.
14. Cihlar, T., E. S. Ho, D. C. Lin, and A. S. Mulato. 2001. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids 20:641-648.
15. Cundy, K. 1999. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin. Pharmacokinet. 36:127-143.
16. Cundy, K. C., C. Sueoka, G. R. Lynch, L. Griffin, W. A. Lee, and J.-P. Shaw. 1998. Pharmacokinetics and bioavailability of the anti-human immunodeficiency virus nucleotide analog 9-[(R)-2-(phosphonomethoxy) propyl]adenine (PMPA) in dogs. Antimicrob. Agents Chemother. 42:687-690.
17. Davies, B., and T. Morris. 1993. Physiological parameters in laboratory animals and humans. Pharm. Res. 10:1093-1095.
18. Deeks, S. G., P. Barditch-Crovo, P. S. Lietman, F. Hwang, K. C. Cundy, J. F. Rooney, N. S. Hellmann, S. Safrin, and J. Kahn. 1998. Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. Antimicrob. Agents Chemother. 42:2380-2384.
19. Deeks, S. G., J. N. Martin, E. Sinclair, J. Harris, T. B. Neilands, H. T. Maecker, E. Hagos, T. Wrin, C. J. Petropoulos, B. Bredt, and J. M. McCune. 2004. Strong cell-mediated immune responses are associated with the maintenance of low-level viremia in antiretroviral-treated individuals with drug-resistant human immunodeficiency virus type 1. J. Infect. Dis. 189:312-321.
20. Durand-Gasselin, L., D. Da Silva, H. Benech, A. Pruvost, and J. Grassi. 2007. Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells. Antimicrob. Agents Chemother. 51:2105-2111.
21. El Sahly, H. M., L. Teeter, T. Zerai, R. A. Andrade, C. Munoz, C. Nnabuife, and R. Hunter. 2006. Serum creatinine changes in HIV-seropositive patients receiving tenofovir. AIDS 20:786-787.
22. Fux, C. A., A. Christen, S. Zgraggen, M. G. Mohaupt, and H. Furrer. 2007. Effect of tenofovir on renal glomerular and tubular function. AIDS 21:1483-1485.
23. Gafni, R. I., R. Hazra, J. C. Reynolds, F. Maldarelli, A. N. Tullio, E. DeCarlo, C. J. Worrell, J. F. Flaherty, K. Yale, B. P. Kearney, and S. L. Zeichner. 2006. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics 118:e711-e718.
24. Gallant, J. E., S. Staszewski, A. L. Pozniak, E. DeJesus, J. M. Suleiman, M. D. Miller, D. F. Coakley, B. Lu, J. J. Toole, and A. K. Cheng. 2004. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292:191-201.
25. Gallant, J. E., M. A. Parish, J. C. Keruly, and R. D. Moore. 2005. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin. Infect. Dis. 40:1194-1198.
26. Giacomet, V., S. Mora, L. Martelli, M. Merlo, M. Sciannamblo, and A. Vigano. 2005. A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children. J. Acquir. Immune Defic. Syndr. 40:448-450.
27. Gitman, M. D., D. Hirschwerk, C. H. Baskin, and P. C. Singhal. 2007. Tenofovir-induced kidney injury. Expert Opin. Drug Saf. 6:155-164.
28. Gribnau, A. A. M., and L. G. M. Geijsberts. 1981. Developmental stages in the rhesus monkey (Macaca mulatta). Springer-Verlag, Berlin, Germany.
29. Hawkins, T., W. Veikley, R. L. St Claire III, B. Guyer, N. Clark, and B. P. Kearney. 2005. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J. Acquir. Immune Defic. Syndr. 39:406-411.
30. Hazra, R., R. I. Gafni, F. Maldarelli, F. M. Balis, A. N. Tullio, E. DeCarlo, C. J. Worrell, S. M. Steinberg, J. Flaherty, K. Yale, B. P. Kearney, and S. L. Zeichner. 2005. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. Pediatrics 116:e846-e854.
31. Hendrie, T. A., P. E. Peterson, J. J. Short, A. F. Tarantal, E. Rothgam, M. I. Hendrie, and A. G. Hendrickx. 1996. Frequency of prenatal loss in a macaque breeding colony. Am. J. Primatol. 40:41-53.
32. Hill, L. R., K. R. Hess, L. C. Stephens, P. T. Tinkey, and R. E. Price. 1999. Comparison of kidney weight and volume to selected anatomical parameters in the adult female rhesus monkey (Macaca mulatta). J. Med. Primatol. 28:67-72.
33. Hill, L. R., K. R. Hess, L. C. Stephens, R. E. Price, and K. N. Gray. 2001. Correlation of kidney weight and volume and selected skeletal parameters to sex in the adult rhesus monkey (Macaca mulatta). J. Med. Primatol. 30: 56-60.
34. Imaoka, T., H. Kusuhara, M. Adachi, J. D. Schuetz, K. Takeuchi, and Y. Sugiyama. 2007. Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol. Pharmacol. 71:619-627.
35. Izzedine, H., J. S. Hulot, D. Vittecoq, J. E. Gallant, S. Staszewski, V. Launay-Vacher, A. Cheng, and G. Deray. 2005. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol. Dial. Transplant. 20:743-746.
36. Jerome, C. P., and P. E. Peterson. 2001. Nonhuman primate models in skeletal research. Bone 29:1-6.
37. Jones, R., J. Stebbing, M. Nelson, G. Moyle, M. Bower, S. Mandalia, and B. Gazzard. 2004. Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently. A cohort and case-control study. J. Acquir. Immune Defic. Syndr. 37:1489-1495.
38. Kearney, B. P., J. F. Flaherty, and J. Shah. 2004. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin. Pharmacokinet. 43:595-612.
39. Lopez-Anaya, A., J. D. Unadkat, L. A. Schumann, and A. L. Smith. 1990. Pharmacokinetics of zidovudine (azidothymidine). II. Development of metabolic and renal clearance pathways in the neonate. J. Acquir. Immune Defic. Syndr. 3:1052-1058.
40. Mauss, S., F. Berger, and G. Schmutz. 2005. Antiretroviral therapy with tenofovir is associated with mild renal dysfunction. AIDS 19:93-95.
41. McChesney, M. B., E. T. Sawai, and C. J. Miller. 1998. Simian immunodeficiency virus, p. 322-345. In R. Ahmed and I. Chen (ed.), Persistent viral infections. John Wiley & Sons, Ltd., New York, NY.
42. Metzner, K. J., J. M. Binley, A. Gettie, P. Marx, D. F. Nixon, and R. I. Connor. 2006. Tenofovir treatment augments anti-viral immunity against drug-resistant SIV challenge in chronically infected rhesus macaques. Retrovirology 3:97.
43. More, C., P. Bettembuk, H. P. Bhattoa, and A. Balogh. 2001. The effects of pregnancy and lactation on bone mineral density. Osteoporos. Int. 12:732-737.
44. Moreno, S., P. Domingo, R. Palacios, J. Santos, V. Falco, J. Murillas, V. Estrada, J. Ena, and M. L. Alvarez. 2006. Renal safety of tenofovir disoproxil fumarate in HIV-1 treatment-experienced patients with adverse events related to prior NRTI use: data from a prospective, observational, multicenter study. J. Acquir. Immune Defic. Syndr. 42:385-387.
45. Moyle, G. J., C. A. Sabin, J. Cartledge, M. Johnson, E. Wilkins, D. Churchill, P. Hay, A. Fakoya, M. Murphy, G. Scullard, C. Leen, and G. Reilly. 2006. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 20:2043-2050.
46. National Research Council. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, DC.
47. Nelson, M. R., C. Katlama, J. S. Montaner, D. A. Cooper, B. Gazzard, B. Clotet, A. Lazzarin, K. Schewe, J. Lange, C. Wyatt, S. Curtis, S. S. Chen, S. Smith, N. Bischofberger, and J. F. Rooney. 2007. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 21:1273-1281.
48. Padilla, S., F. Gutierrez, M. Masia, V. Canovas, and C. Orozco. 2005. Low frequency of renal function impairment during one-year of therapy with tenofovir-containing regimens in the real-world: a case-control study. AIDS Patient Care STDS 19:421-424.
49. Pozniak, A. L., J. E. Gallant, E. Dejesus, J. R. Arribas, B. Gazzard, R. E. Campo, S. S. Chen, D. McColl, J. Enejosa, J. J. Toole, and A. K. Cheng. 2006. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes - a 96-week analysis. J. Acquir. Immune Defic. Syndr. 43:535-540.
50. Pruvost, A., E. Negredo, H. Benech, F. Theodoro, J. Puig, E. Grau, E. Garcia, J. Molto, J. Grassi, and B. Clotet. 2005. Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 49:1907-1914.
51. Ray, A. S., T. Cihlar, K. L. Robinson, L. Tong, J. E. Vela, M. D. Fuller, L. M. Wieman, E. J. Eisenberg, and G. R. Rhodes. 2006. Mechanism of active renal tubular efflux of tenofovir. Antimicrob. Agents Chemother. 50:3297-3304.
52. Roberts, J., E. W. Ford, and J. L. Southers. 1998. Urinary system, p. 312-323. In B. T. Bennett, C. R. Abee, and R. Henrickson (ed.), Nonhuman primates in biomedical research diseases. Academic Press, San Diego, CA.
53. Sax, P. E., J. E. Gallant, and P. E. Klotman. 2007. Renal safety of tenofovir disoproxil fumarate. AIDS Read. 17:90-92, 99-104, C3.
54. Shaw, J. P., C. M. Sueoka, R. Oliyai, W. A. Lee, M. N. Arimilli, C. Kim, and K. C. Cundy. 1997. Metabolism and pharmacokinetics of a novel oral prodrug of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. Pharm. Res. 14:1824-1829.
55. Tarantal, A. F., M. L. Marthas, J.-P. Shaw, K. Cundy, and N. Bischofberger. 1999. Administration of 9-[2-(R)-(phosphonomethoxy) propyl]adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): safety and efficacy studies. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 20:323-333.
56. Tarantal, A. F., A. Castillo, J. E. Ekert, N. Bischofberger, and R. B. Martin. 2002. Fetal and maternal outcome after administration of tenofovir to gravid rhesus monkeys (Macaca mulatta). J. Acquir. Immune Defic. Syndr. 29:207-220.
57. Tsai, C.-C., K. E. Follis, T. W. Beck, A. Sabo, R. F. Grant, N. Bischofberger, and R. E. Benveniste. 1995. Prevention of simian immunodeficiency virus infection in macaques by 9-(2-phosphonylmethoxypropyl) adenine (PMPA). Science 270:1197-1199.
58. Van Rompay, K. K., J. A. Johnson, E. J. Blackwood, R. P. Singh, J. Lipscomb, T. B. Matthews, M. L. Marthas, N. C. Pedersen, N. Bischofberger, W. Heneine, and T. W. North. 2007. Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection. Retrovirology 4:25.
59. Van Rompay, K. K. A., J. M. Cherrington, M. L. Marthas, C. J. Berardi, A. S. Mulato, A. Spinner, R. P. Tarara, D. R. Canfield, S. Telm, N. Bischofberger, and N. C. Pedersen. 1996. 9-[2-(Phosphonomethoxy)propyl] adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques. Antimicrob. Agents Chemother. 40:2586-2591.
60. Van Rompay, K. K. A., J. M. Cherrington, M. L. Marthas, P. D. Lamy, P. J. Dailey, D. R. Canfield, R. P. Tarara, N. Bischofberger, and N. C. Pedersen. 1999. 9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPA. Antimicrob. Agents Chemother. 43: 802-812.
61. Van Rompay, K. K. A., M. D. Miller, M. L. Marthas, N. A. Margot, P. J. Dailey, R. P. Tarara, D. R. Canfield, J. M. Cherrington, N. L. Aguirre, N. Bischofberger, and N. C. Pedersen. 2000. Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonometnoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA. J. Virol. 74: 1767-1774.
62. Van Rompay, K. K. A., M. B. McChesney, N. L. Aguirre, K. A. Schmidt, N. Bischofberger, and M. L. Marthas. 2001. Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection. J. Infect. Dis. 184:429-438.
63. Van Rompay, K. K. A., L. L. Brignolo, D. J. Meyer, C. Jerome, R. Tarara, A. Spinner, M. Hamilton, L. L. Hirst, D. R. Bennett, D. R. Canfield, T. G. Dearman, W. Von Morgenland, P. C. Allen, C. Valverde, A. B. Castillo, R. B. Martin, V. F. Samii, R. Bendele, J. Desjardins, M. L. Marthas, N. C. Pedersen, and N. Bischofberger. 2004. Biological effects of short-term and prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob. Agents Chemother. 48:1469-1487.
64. Van Rompay, K. K. A., R. Singh, L. Brignolo, J. R. Lawson, K. A. Schmidt, B. Pahar, D. R. Canfield, R. P. Tarara, N. Bischofberger, and M. Marthas. 2004. The clinical benefits of tenofovir for simian immunodeficiency virus-infected macaques are larger than predicted by its effects on standard viral and immunological parameters. J. Acquir. Immune Defic. Syndr. 36:900-914.
65. + cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment. J. Virol. 78:5324-5337.
66. Van Rompay, K. K. A. 2005. Antiretroviral drug studies in non-human primates: a valid animal model for innovative drug efficacy and pathogenesis studies. AIDS Rev. 7:67-83.
67. Van Rompay, K. K. A., B. P. Kearney, J. J. Sexton, R. Colón, J. R. Lawson, E. J. Blackwood, W. A. Lee, N. Bischofberger, and M. L. Marthas. 2006. Evaluation of oral tenofovir disoproxil fumarate and topical tenofovir GS-7340 to protect infant macaques against repeated oral challenges with virulent simian immunodeficiency virus. J. Acquir. Immune Defic. Syndr. 43:6-14.
68. Vela, J. E., L. Y. Olson, A. Huang, A. Fridland, and A. S. Ray. 2007. Simultaneous quantitation of the nucleotide analog adefovir, its phosphorylated anabolites and 2′-deoxyadenosine triphosphate by ion-pairing LC/MS/MS. J. Chromatogr. B 848:335-343.
69. Vigano, A., G. V. Zuccotti, L. Martelli, V. Giacomet, L. Cafarelli, S. Borgonovo, S. Beretta, G. Rombola, and S. Mora. 2007. Renal safety of tenofovir in HIV-infected children: a prospective, 96-week longitudinal study. Clin. Drug Investig. 27:573-581.
70. Winston, A., J. Amin, P. Mallon, D. Marriott, A. Carr, D. A. Cooper, and S. Emery. 2006. Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy. HIV Med. 7:105-111.
71. Zimmermann, A. E., T. Pizzoferrato, J. Bedford, A. Morris, R. Hoffman, and G. Braden. 2006. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin. Infect. Dis. 42:283-290.
72. Zoetis, T., and M. Hurtt. 2003. Species comparison of anatomical and functional renal development. Birth Defects Res. B 68:111-120.